SARS-CoV-2 evolution during prolonged infection in immunocompromised patients

Andrew D Marques,Jevon Graham-Wooten,Ayannah S Fitzgerald,Ashley Sobel Leonard,Emma J Cook,John K Everett,Kyle G Rodino,Louise H Moncla,Brendan J Kelly,Ronald G Collman,Frederic D Bushman,Andrew D. Marques,Ayannah S. Fitzgerald,Emma J. Cook,John K. Everett,Kyle G. Rodino,Louise H. Moncla,Brendan J. Kelly,Ronald G. Collman,Frederic D. Bushman

DOI: https://doi.org/10.1128/mbio.00110-24

IF: 6.4

2024-02-18

mBio

Abstract:ABSTRACT Prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in immunocompromised patients provides an opportunity for viral evolution, potentially leading to the generation of new pathogenic variants. To investigate the pathways of viral evolution, we carried out a study on five patients experiencing prolonged SARS-CoV-2 infection (quantitative polymerase chain reaction-positive for 79–203 days) who were immunocompromised due to treatment for lymphoma or solid organ transplantation. For each timepoint analyzed, we generated at least two independent viral genome sequences to assess the heterogeneity and control for sequencing error. Four of the five patients likely had prolonged infection; the fifth apparently experienced a reinfection. The rates of accumulation of substitutions in the viral genome per day were higher in hospitalized patients with prolonged infection than those estimated for the community background. The spike coding region accumulated a significantly greater number of unique mutations than other viral coding regions, and the mutation density was higher. Two patients were treated with monoclonal antibodies (bebtelovimab and sotrovimab); by the next sampled timepoint, each virus population showed substitutions associated with monoclonal antibody resistance as the dominant forms ( spike K444N and spike E340D). All patients received remdesivir, but remdesivir-resistant substitutions were not detected. These data thus help elucidate the trends of emergence, evolution, and selection of mutational variants within long-term infected immunocompromised individuals. IMPORTANCE SARS-CoV-2 is responsible for a global pandemic, driven in part by the emergence of new viral variants. Where do these new variants come from? One model is that long-term viral persistence in infected individuals allows for viral evolution in response to host pressures, resulting in viruses more likely to replicate efficiently in humans. In this study, we characterize replication in several hospitalized and long-term infected individuals, documenting efficient pathways of viral evolution.

microbiology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the viral evolution path during the long - term infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS - CoV - 2) in patients with impaired immune function. Specifically, the researchers hope to understand the following aspects by analyzing the viral genome changes in 5 patients with impaired immune function:

1. **Rate of virus evolution**: The researchers hope to quantify whether the speed of virus genome mutation accumulation in patients with impaired immune function is faster than that in the general population.
2. **Mutation pattern**: The researchers hope to determine which viral gene regions are more likely to accumulate mutations, especially whether the Spike - coding region is more prone to mutation.
3. **Drug resistance**: The researchers hope to evaluate whether the virus will develop drug - resistant mutations in patients treated with monoclonal antibodies and antiviral drugs, and whether these mutations will dominate in the virus population.
4. **Possibility of reinfection**: The researchers hope to confirm whether there is a reinfection situation during the long - term infection process, and the relationship between the reinfected virus strain and the initial infected strain.

Through these studies, the paper hopes to better understand the evolution mechanism of SARS - CoV - 2 in patients with impaired immune function, so as to provide a scientific basis for future epidemic prevention and control and treatment strategies.